Homepage
Ceretas is developing a non-invasive, safe and portable therapeutic ultrasound platform to treat diseases of the brain.
ceretas.com.auCrawled Nov 10, 2026
Ceretas is developing a non-invasive, safe and portable therapeutic ultrasound platform to treat diseases of the brain.
Ceretas, a medical technology firm spun out from the University of Queensland, secures strong demand for its initial public offering (IPO) and accelerates plans to list on the local stock exchange. The company aims to use IPO proceeds to advance its clinical trials, though specific trial details or funding amounts remain unstated.
Researchers at the Queensland Brain Institute (QBI) demonstrate that an ultrasound-based treatment for dementia passes initial safety checks in human trials. The device, developed in-house, undergoes testing to assess its viability as a non-invasive therapeutic approach for cognitive impairment. Early results suggest no adverse effects in participants, marking progress toward potential clinical applications.
Ceretas secures a **$2.4 million Australian government grant** to advance its **Alzheimer’s therapy device**, a potential breakthrough in treating the disease. The funding supports development of a novel treatment approach targeting cognitive decline. The device represents one of Australia’s first medical innovations in Alzheimer’s care, aiming to improve patient outcomes through non-invasive methods.
Ceretas, an Australian MedTech company, raises **$1 million in seed funding** to develop its **portable, non-invasive ultrasound device** for treating dementia and neurological conditions. The funding accelerates clinical research and regulatory progress, positioning the company toward a potential **initial public offering (IPO)**. The device targets cost-effective, accessible therapy options for patients.
The University of Queensland (UQ) has licensed its therapeutic ultrasound treatment for Alzheimer’s disease to a newly formed startup. The technology, developed by UQ researcher Matt Pelekanos, targets non-invasive brain stimulation as a potential intervention for neurodegenerative conditions. The startup will advance clinical development and commercialization of the device.

Ceretas is a clinical-stage company that develops a portable, non-invasive focused ultrasound platform for Alzheimer's and other neurodegenerative diseases.